NCT04241640

Brief Summary

Video-assisted thoracoscopic (VATs) lobectomy is mild to moderately pain procedure. For conventional thoracotomy, there are many invasive pain control such as epidural analgesia, paravertebral block. However, for VATs, the invasive pain control somehow are too invasive. Nefopam is non-opioid painkilling medication, Serotonin, norepinephrine, dopamine reuptake inhibitor. Many study were demonstrated positive outcome of nefopam usage in many operation such as abdominal surgery, laparocopic surgery, orthopedic surgery. Nevertheless, nefopam for VATs is not well studied yet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2020

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 27, 2020

Completed
7 months until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
Last Updated

November 20, 2024

Status Verified

June 1, 2023

Enrollment Period

1.9 years

First QC Date

January 23, 2020

Last Update Submit

November 18, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • morphine consumption in first 24 hours post-operative

    morphine consumption record from patient-controlled analgesia machine in 24 hours post-operative

    24 hours

Secondary Outcomes (2)

  • numeric pain score

    24 hours

  • side effect of nefopam

    24 hours

Study Arms (2)

Nefopam group[

EXPERIMENTAL
Drug: Nefopam 20 MG/ML

placebo group

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative

Nefopam group[

Placebo

placebo group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Schedule to video-assisted thoracoscopic surgery : VATs lobectomy
  • Can operate a patient-controlled analgesia (PCA) device
  • No contraindication for nefopam

You may not qualify if:

  • Epilepsy, on monoamine oxidase (MAO) inhibitors, glaucoma
  • Creatinine clearance \< 60 ml/min
  • Liver disease: child-pugh score B or C
  • Allergy to nefopam
  • Chronic opioid use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

faculty of medicine Siriraj hospital

Bangkok, 10600, Thailand

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Nefopam

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

OxazocinesAzocinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 23, 2020

First Posted

January 27, 2020

Study Start

September 1, 2020

Primary Completion

August 1, 2022

Study Completion

March 1, 2023

Last Updated

November 20, 2024

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations